MannKind reported Q4 FY2025 total revenues of USD 112 million, up 46% year-on-year, and FY2025 total revenues of USD 349 million, up 22%. In Q4, commercial product sales were USD 50.4 million (from USD 23.1 million a year earlier), including Afrezza net sales of USD 22.9 million (+25%) and Furoscix net sales of USD 23.2 million (recorded following the October 7, 2025 acquisition of scPharmaceuticals). Q4 royalties were USD 33.6 million (+24%) and collaborations and services revenue was USD 28.0 million (+5%). For Q4, MannKind posted a net loss of USD 15.9 million versus net income of USD 7.4 million a year earlier, reflecting higher expenses; SG&A rose to USD 58.4 million (+144%) and R&D increased to USD 27.6 million (+148%). FY2025 net income was USD 5.9 million versus USD 27.6 million in FY2024, while FY SG&A increased to USD 144.1 million (+53%) and FY R&D rose to USD 66.3 million (+45%). Cash, cash equivalents and investments totaled USD 176 million at December 31, 2025. Business updates included completion of the scPharma acquisition (October 7, 2025), FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. MannKind also said enrollment is underway in the Phase 1b INFLO-1 study for nintedanib DPI (MNKD-201) with topline data expected in 2H 2026, and it initiated a Phase 2 IPF trial (INFLO-2) with plans to enroll the first patient in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260800PRIMZONEFULLFEED9661890) on February 26, 2026, and is solely responsible for the information contained therein.